Complement C3a Receptor (C3aR) Mediates Vascular Dysfunction, Hippocampal Pathology, and Cognitive Impairment in a Mouse Model of VCID.
Cerebral blood flow (CBF), White matter degeneration (WMD)
Complement C3a receptor (C3aR)
Inflammation
Vascular contributions to cognitive impairment and dementia (VCID)
Journal
Translational stroke research
ISSN: 1868-601X
Titre abrégé: Transl Stroke Res
Pays: United States
ID NLM: 101517297
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
11
01
2022
accepted:
28
01
2022
revised:
24
01
2022
pubmed:
9
3
2022
medline:
24
8
2022
entrez:
8
3
2022
Statut:
ppublish
Résumé
Vascular contributions to cognitive impairment and dementia (VCID) secondary to chronic mild-moderate cerebral ischemia underlie a significant percentage of cases of dementia. We previously reported that either genetic deficiency of the complement C3a receptor (C3aR) or its pharmacological inhibition protects against cerebral ischemia in rodents, while others have implicated C3aR in the pathogenesis seen in rodent transgenic models of Alzheimer's disease. In the present study, we evaluated the role of complement C3a-C3aR signaling in the onset and progression of VCID. We utilized the bilateral common carotid artery stenosis (BCAS) model to induce VCID in male C57BL/6 wild-type and C3aR-knockout (C3aR
Identifiants
pubmed: 35258803
doi: 10.1007/s12975-022-00993-x
pii: 10.1007/s12975-022-00993-x
doi:
Substances chimiques
Receptors, Complement
0
complement C3a receptor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
816-829Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Corriveau RA, Bosetti F, Emr M, Gladman JT, Koenig JI, Moy CS, et al. The science of vascular contributions to cognitive impairment and dementia (VCID): a framework for advancing research priorities in the cerebrovascular biology of cognitive decline. Cell Mol Neurobiol. 2016;36(2):281–8.
pubmed: 27095366
pmcid: 4859348
doi: 10.1007/s10571-016-0334-7
Khan MB, Hafez S, Hoda MN, Baban B, Wagner J, Awad ME, et al. Chronic remote ischemic conditioning is cerebroprotective and induces vascular remodeling in a VCID model. Transl Stroke Res. 2018;9(1):51–63.
pubmed: 28755277
doi: 10.1007/s12975-017-0555-1
Iadecola C, Duering M, Hachinski V, Joutel A, Pendlebury ST, Schneider JA, et al. Vascular cognitive impairment and dementia: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019;73(25):3326–44.
pubmed: 31248555
pmcid: 6719789
doi: 10.1016/j.jacc.2019.04.034
Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(9):2672–713.
pubmed: 21778438
pmcid: 3778669
doi: 10.1161/STR.0b013e3182299496
O’Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386(10004):1698–706.
pubmed: 26595643
doi: 10.1016/S0140-6736(15)00463-8
Matsui Y, Tanizaki Y, Arima H, Yonemoto K, Doi Y, Ninomiya T, et al. Incidence and survival of dementia in a general population of Japanese elderly: the Hisayama study. J Neurol Neurosurg Psychiatry. 2009;80(4):366–70.
pubmed: 18977814
doi: 10.1136/jnnp.2008.155481
Snyder HM, Corriveau RA, Craft S, Faber JE, Greenberg SM, Knopman D, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer’s disease. Alzheimers Dement. 2015;11(6):710–7.
pubmed: 25510382
doi: 10.1016/j.jalz.2014.10.008
Nishio K, Ihara M, Yamasaki N, Kalaria RN, Maki T, Fujita Y, et al. A mouse model characterizing features of vascular dementia with hippocampal atrophy. Stroke. 2010;41(6):1278–84.
pubmed: 20448204
doi: 10.1161/STROKEAHA.110.581686
Shibata M, Yamasaki N, Miyakawa T, Kalaria RN, Fujita Y, Ohtani R, et al. Selective impairment of working memory in a mouse model of chronic cerebral hypoperfusion. Stroke. 2007;38(10):2826–32.
pubmed: 17761909
doi: 10.1161/STROKEAHA.107.490151
Shibata M, Ohtani R, Ihara M, Tomimoto H. White matter lesions and glial activation in a novel mouse model of chronic cerebral hypoperfusion. Stroke. 2004;35(11):2598–603.
pubmed: 15472111
doi: 10.1161/01.STR.0000143725.19053.60
Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80(4):844–66.
pubmed: 24267647
doi: 10.1016/j.neuron.2013.10.008
de la Torre JC, Aliev G. Inhibition of vascular nitric oxide after rat chronic brain hypoperfusion: spatial memory and immunocytochemical changes. J Cereb Blood Flow Metab. 2005;25(6):663–72.
pubmed: 15703700
doi: 10.1038/sj.jcbfm.9600057
Liu Q, He S, Groysman L, Shaked D, Russin J, Scotton TC, et al. White matter injury due to experimental chronic cerebral hypoperfusion is associated with C5 deposition. PLoS One. 2013;8(12):e84802.
pubmed: 24386419
pmcid: 3875540
doi: 10.1371/journal.pone.0084802
Kitaguchi H, Tomimoto H, Ihara M, Shibata M, Uemura K, Kalaria RN, et al. Chronic cerebral hypoperfusion accelerates amyloid beta deposition in APPSwInd transgenic mice. Brain Res. 2009;1294:202–10.
pubmed: 19646974
doi: 10.1016/j.brainres.2009.07.078
O’Sullivan M, Lythgoe DJ, Pereira AC, Summers PE, Jarosz JM, Williams SC, et al. Patterns of cerebral blood flow reduction in patients with ischemic leukoaraiosis. Neurology. 2002;59(3):321–6.
pubmed: 12177363
doi: 10.1212/WNL.59.3.321
Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer’s disease. Nat Rev Neurosci. 2004;5(5):347–60.
pubmed: 15100718
doi: 10.1038/nrn1387
Promjunyakul N, Lahna D, Kaye JA, Dodge HH, Erten-Lyons D, Rooney WD, et al. Characterizing the white matter hyperintensity penumbra with cerebral blood flow measures. Neuroimage Clin. 2015;8:224–9.
pubmed: 26106546
pmcid: 4473817
doi: 10.1016/j.nicl.2015.04.012
Promjunyakul NO, Lahna DL, Kaye JA, Dodge HH, Erten-Lyons D, Rooney WD, et al. Comparison of cerebral blood flow and structural penumbras in relation to white matter hyperintensities: a multi-modal magnetic resonance imaging study. J Cereb Blood Flow Metab. 2016;36(9):1528–36.
pubmed: 27270266
pmcid: 5010096
doi: 10.1177/0271678X16651268
de Vries HE, Kooij G, Frenkel D, Georgopoulos S, Monsonego A, Janigro D. Inflammatory events at blood-brain barrier in neuroinflammatory and neurodegenerative disorders: implications for clinical disease. Epilepsia. 2012;53(Suppl 6):45–52.
pubmed: 23134495
pmcid: 4853914
doi: 10.1111/j.1528-1167.2012.03702.x
Wang F, Cao Y, Ma L, Pei H, Rausch WD, Li H. Dysfunction of cerebrovascular endothelial cells: prelude to vascular dementia. Front Aging Neurosci. 2018;10:376.
pubmed: 30505270
pmcid: 6250852
doi: 10.3389/fnagi.2018.00376
Manukjan N, Ahmed Z, Fulton D, Blankesteijn WM, Foulquier S. A systematic review of WNT signaling in endothelial cell oligodendrocyte interactions: potential relevance to cerebral small vessel disease. Cells. 2020;9(6):1545.
Alafuzoff I, Adolfsson R, Grundke-Iqbal I, Winblad B. Blood-brain barrier in Alzheimer dementia and in non-demented elderly. An immunocytochemical study. Acta Neuropathol. 1987;73(2):160–6.
pubmed: 3300132
doi: 10.1007/BF00693782
Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease–systematic review and meta-analysis. Neurobiol Aging. 2009;30(3):337–52.
pubmed: 17869382
doi: 10.1016/j.neurobiolaging.2007.07.015
Schreiber S, Bueche CZ, Garz C, Braun H. Blood brain barrier breakdown as the starting point of cerebral small vessel disease? - New insights from a rat model. Exp Transl Stroke Med. 2013;5(1):4.
pubmed: 23497521
pmcid: 3618264
doi: 10.1186/2040-7378-5-4
Skoog I, Wallin A, Fredman P, Hesse C, Aevarsson O, Karlsson I, et al. A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer’s disease and vascular dementia. Neurology. 1998;50(4):966–71.
pubmed: 9566380
doi: 10.1212/WNL.50.4.966
Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57(2):178–201.
pubmed: 18215617
doi: 10.1016/j.neuron.2008.01.003
Sewell DL, Nacewicz B, Liu F, Macvilay S, Erdei A, Lambris JD, et al. Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist. J Neuroimmunol. 2004;155(1–2):55–63.
pubmed: 15342196
pmcid: 4766842
doi: 10.1016/j.jneuroim.2004.06.003
Mocco J, Mack WJ, Ducruet AF, Sosunov SA, Sughrue ME, Hassid BG, et al. Complement component C3 mediates inflammatory injury following focal cerebral ischemia. Circ Res. 2006;99(2):209–17.
pubmed: 16778128
doi: 10.1161/01.RES.0000232544.90675.42
Engstrom G, Hedblad B, Janzon L, Lindgarde F. Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort study. Eur J Cardiovasc Prev Rehabil. 2007;14(3):392–7.
pubmed: 17568238
doi: 10.1097/01.hjr.0000244582.30421.b2
Cojocaru IM, Cojocaru M, Tanasescu R, Burcin C, Atanasiu AN, Petrescu AM, et al. Changes in plasma levels of complement in patients with acute ischemic stroke. Rom J Intern Med. 2008;46(1):77–80.
pubmed: 19157274
Ducruet AF, Hassid BG, Mack WJ, Sosunov SA, Otten ML, Fusco DJ, et al. C3a receptor modulation of granulocyte infiltration after murine focal cerebral ischemia is reperfusion dependent. J Cereb Blood Flow Metab. 2008;28(5):1048–58.
pubmed: 18197178
doi: 10.1038/sj.jcbfm.9600608
Rynkowski MA, Kim GH, Garrett MC, Zacharia BE, Otten ML, Sosunov SA, et al. C3a receptor antagonist attenuates brain injury after intracerebral hemorrhage. J Cereb Blood Flow Metab. 2009;29(1):98–107.
pubmed: 18728680
doi: 10.1038/jcbfm.2008.95
Ducruet AF, Zacharia BE, Sosunov SA, Gigante PR, Yeh ML, Gorski JW, et al. Complement inhibition promotes endogenous neurogenesis and sustained anti-inflammatory neuroprotection following reperfused stroke. PLoS One. 2012;7(6):e38664.
pubmed: 22761695
pmcid: 3383680
doi: 10.1371/journal.pone.0038664
Stokowska A, Olsson S, Holmegaard L, Jood K, Blomstrand C, Jern C, et al. Cardioembolic and small vessel disease stroke show differences in associations between systemic C3 levels and outcome. PLoS One. 2013;8(8):e72133.
pubmed: 23977229
pmcid: 3748011
doi: 10.1371/journal.pone.0072133
Zhang LY, Pan J, Mamtilahun M, Zhu Y, Wang L, Venkatesh A, et al. Microglia exacerbate white matter injury via complement C3/C3aR pathway after hypoperfusion. Theranostics. 2020;10(1):74–90.
pubmed: 31903107
pmcid: 6929610
doi: 10.7150/thno.35841
Zhang B, Yang N, Gao C. Is plasma C3 and C4 levels useful in young cerebral ischemic stroke patients? Associations with prognosis at 3 months. J Thromb Thrombolysis. 2015;39(2):209–14.
pubmed: 24938594
doi: 10.1007/s11239-014-1100-7
Propson NE, Roy ER, Litvinchuk A, Köhl J, Zheng H. Endothelial C3a receptor mediates vascular inflammation and blood-brain barrier permeability during aging. J Clin Invest. 2021;131(1): e140966.
Litvinchuk A, Wan YW, Swartzlander DB, Chen F, Cole A, Propson NE, et al. Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer’s disease. Neuron. 2018;100(6):1337-53.e5.
pubmed: 30415998
pmcid: 6309202
doi: 10.1016/j.neuron.2018.10.031
Ihara M, Tomimoto H. Lessons from a mouse model characterizing features of vascular cognitive impairment with white matter changes. J Aging Res. 2011;2011:978761.
pubmed: 22132331
pmcid: 3216359
doi: 10.4061/2011/978761
Ahmad S, Kindelin A, Khan SA, Ahmed M, Hoda MN, Bhatia K, et al. C3a receptor inhibition protects brain endothelial cells against oxygen-glucose deprivation/reperfusion. Exp Neurobiol. 2019;28(2):216–28.
pubmed: 31138990
pmcid: 6526115
doi: 10.5607/en.2019.28.2.216
Ahmad S, Pandya C, Kindelin A, Bhatia K, Chaudhary R, Dwivedi AK, et al. C3a receptor antagonist therapy is protective with or without thrombolysis in murine thromboembolic stroke. Br J Pharmacol. 2020;177(11):2466–77.
pubmed: 31975437
pmcid: 7205805
doi: 10.1111/bph.14989
Bhatia K, Ahmad S, Kindelin A, Ducruet AF. Complement C3a receptor-mediated vascular dysfunction: a complex interplay between aging and neurodegeneration. J Clin Invest. 2021;131(1): e144348.
Coulthard LG, Woodruff TM. Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth. J Immunol. 2015;194(8):3542–8.
pubmed: 25848071
doi: 10.4049/jimmunol.1403068
Stokowska A, Atkins AL, Morán J, Pekny T, Bulmer L, Pascoe MC, et al. Complement peptide C3a stimulates neural plasticity after experimental brain ischaemia. Brain. 2017;140(2):353–69.
pubmed: 27956400
doi: 10.1093/brain/aww314
De Vis JB, Hendrikse J, Bhogal A, Adams A, Kappelle LJ, Petersen ET. Age-related changes in brain hemodynamics; a calibrated MRI study. Hum Brain Mapp. 2015;36(10):3973–87.
pubmed: 26177724
pmcid: 6869092
doi: 10.1002/hbm.22891
del Ser T, Bermejo F, Portera A, Arredondo JM, Bouras C, Constantinidis J. Vascular dementia. A clinicopathological study. J Neurol Sci. 1990;96(1):1–17.
pubmed: 2351984
doi: 10.1016/0022-510X(90)90052-O
Scheel P, Puls I, Becker G, Schoning M. Volume reduction in cerebral blood flow in patients with vascular dementia. Lancet. 1999;354(9196):2137.
pubmed: 10609827
doi: 10.1016/S0140-6736(99)04016-7
Schuff N, Matsumoto S, Kmiecik J, Studholme C, Du A, Ezekiel F, et al. Cerebral blood flow in ischemic vascular dementia and Alzheimer’s disease, measured by arterial spin-labeling magnetic resonance imaging. Alzheimers Dement. 2009;5(6):454–62.
pubmed: 19896584
pmcid: 2802181
doi: 10.1016/j.jalz.2009.04.1233
Khan MB, Hoda MN, Vaibhav K, Giri S, Wang P, Waller JL, et al. Remote ischemic postconditioning: harnessing endogenous protection in a murine model of vascular cognitive impairment. Transl Stroke Res. 2015;6(1):69–77.
pubmed: 25351177
doi: 10.1007/s12975-014-0374-6
Hess DC, Khan MB, Hoda N, Morgan JC. Remote ischemic conditioning: a treatment for vascular cognitive impairment. Brain Circ. 2015;1(2):133–9.
pubmed: 30221201
doi: 10.4103/2394-8108.172885
Dalby RB, Eskildsen SF, Videbech P, Frandsen J, Mouridsen K, Sorensen L, et al. Oxygenation differs among white matter hyperintensities, intersected fiber tracts and unaffected white matter. Brain Commun. 2019;1(1):fcz033.
pubmed: 32954272
pmcid: 7425421
doi: 10.1093/braincomms/fcz033
Apostolova LG, Dutton RA, Dinov ID, Hayashi KM, Toga AW, Cummings JL, et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol. 2006;63(5):693–9.
pubmed: 16682538
doi: 10.1001/archneur.63.5.693
Apostolova LG, Mosconi L, Thompson PM, Green AE, Hwang KS, Ramirez A, et al. Subregional hippocampal atrophy predicts Alzheimer’s dementia in the cognitively normal. Neurobiol Aging. 2010;31(7):1077–88.
pubmed: 18814937
doi: 10.1016/j.neurobiolaging.2008.08.008
Carmichael OT, Kuller LH, Lopez OL, Thompson PM, Dutton RA, Lu A, et al. Cerebral ventricular changes associated with transitions between normal cognitive function, mild cognitive impairment, and dementia. Alzheimer Dis Assoc Disord. 2007;21(1):14–24.
pubmed: 17334268
pmcid: 2879163
doi: 10.1097/WAD.0b013e318032d2b1
Yousef H, Czupalla CJ, Lee D, Chen MB, Burke AN, Zera KA, et al. Aged blood impairs hippocampal neural precursor activity and activates microglia via brain endothelial cell VCAM1. Nat Med. 2019;25(6):988–1000.
pubmed: 31086348
pmcid: 6642642
doi: 10.1038/s41591-019-0440-4
Dulken BW, Buckley MT, Navarro Negredo P, Saligrama N, Cayrol R, Leeman DS, et al. Single-cell analysis reveals T cell infiltration in old neurogenic niches. Nature. 2019;571(7764):205–10.
pubmed: 31270459
pmcid: 7111535
doi: 10.1038/s41586-019-1362-5
Gate D, Saligrama N, Leventhal O, Yang AC, Unger MS, Middeldorp J, et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer’s disease. Nature. 2020;577(7790):399–404.
pubmed: 31915375
pmcid: 7445078
doi: 10.1038/s41586-019-1895-7
Lee JD, Taylor SM, Woodruff TM. Is the C3a receptor antagonist SB290157 a useful pharmacological tool? Br J Pharmacol. 2020;177(24):5677–8.
pubmed: 33073351
pmcid: 7707084
doi: 10.1111/bph.15264